Reference · cited facts
MOTS-c
Half-life Uncharacterized in humansResearch use · not FDA-approvedReviewed July 2026
Educational information and a math tool only — not medical advice, a dose recommendation, or an endorsement of peptide use. Not FDA-approved for human use. Consult a licensed healthcare provider before starting, stopping, or changing anything.
Class / mechanism
MOTS-c is a mitochondrial-derived peptide studied primarily in preclinical (cell and animal) models.
SOURCE [1]
Regulatory status
Not FDA-approved. Removed from 503A Category-2 (2026); under PCAC review (July 2026).
FDA · July 2026
Reported half-life
Uncharacterized in humans
NO RELIABLE HUMAN SOURCE
Human evidence
Preclinical only
LITERATURE
What the literature reports
- MOTS-c is a mitochondrial-derived peptide studied primarily in preclinical (cell and animal) models.
- Its first human randomized controlled trial (NCT07505745) is a recent development; robust human efficacy data do not yet exist.
- No established human half-life has been characterized.
Honest caveats
- • Evidence is preclinical — no robust human data exists.
- • Not FDA-approved; regulatory status is in flux.
Reconstitution calculator
Enter your own vial size, BAC water and target dose — get exact syringe units.
Sources